OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IGG

Abstract

The invention concerns ofatumumab for use in the treatment of multiple sclerosis (MS), wherein the treatment is a long-term treatment and wherein serum IgG level is maintained during the treatment. The invention further relates to B cell and/or T cell inhibitors for use in the treatment of MS, said treatment comprising monitoring serum IgG level and selecting ofatumumab as the B cell and/or T cell inhibitor if the serum IgG level decreases and/or said treatment comprising assessing the predisposition of the patient for an increased risk of infections and selecting ofatumumab as the B cell and/or T cell inhibitor if a predisposition is identified. The invention further relates to ofatumumab for use in the treatment of multiple sclerosis, wherein patients having a lowered serum IgG level are treated and/or wherein patients having risk factors associated with serum Ig levels, in particular serum IgG levels, are treated.

Inventors

PINGILI, Ratnakar
MERSCHHEMKE, Martin

Assignees

Novartis AG

Dates

Publication Date: 20260506
Application Date: 20210409